Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
Kouvaraki M, Zerdes I, Sifakis EG, Sarafidis M, Matikas A, Tzoras E, Kjällquist U, Stathopoulou K, Lövrot J, Alkodsi A, Hartman J, Sotiriou C, Richard F, Hatschek T, Herold N, Bergh J, Rassidakis GZ, Foukakis T. Kouvaraki M, et al. Among authors: hartman j. Int J Cancer. 2024 Dec 27. doi: 10.1002/ijc.35319. Online ahead of print. Int J Cancer. 2024. PMID: 39729390
Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
Kjällquist U, Erlandsson R, Tobin NP, Alkodsi A, Ullah I, Stålhammar G, Karlsson E, Hatschek T, Hartman J, Linnarsson S, Bergh J. Kjällquist U, et al. Among authors: hartman j. BMC Cancer. 2018 Feb 12;18(1):174. doi: 10.1186/s12885-018-4021-6. BMC Cancer. 2018. PMID: 29433456 Free PMC article.
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Zerdes I, Sifakis EG, Matikas A, Chrétien S, Tobin NP, Hartman J, Rassidakis GZ, Bergh J, Foukakis T. Zerdes I, et al. Among authors: hartman j. Mol Oncol. 2020 May;14(5):951-963. doi: 10.1002/1878-0261.12654. Epub 2020 Mar 20. Mol Oncol. 2020. PMID: 32115850 Free PMC article.
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.
Matikas A, Johansson H, Grybäck P, Bjöhle J, Acs B, Boyaci C, Lekberg T, Fredholm H, Elinder E, Margolin S, Isaksson-Friman E, Bosch A, Lindman H, Adra J, Andersson A, Agartz S, Hellström M, Zerdes I, Hartman J, Bergh J, Hatschek T, Foukakis T. Matikas A, et al. Among authors: hartman j. Clin Cancer Res. 2023 Feb 1;29(3):532-540. doi: 10.1158/1078-0432.CCR-22-2829. Clin Cancer Res. 2023. PMID: 36449695 Clinical Trial.
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.
Zerdes I, Simonetti M, Matikas A, Harbers L, Acs B, Boyaci C, Zhang N, Salgkamis D, Agartz S, Moreno-Ruiz P, Bai Y, Rimm DL, Hartman J, Mezheyeuski A, Bergh J, Crosetto N, Foukakis T. Zerdes I, et al. Among authors: hartman j. NPJ Breast Cancer. 2021 Nov 19;7(1):144. doi: 10.1038/s41523-021-00352-3. NPJ Breast Cancer. 2021. PMID: 34799582 Free PMC article.
1,155 results